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T12 and T16 are cost-effective. In deciding between
them, the size of the available budget must be brought to
bear. T12 ensures greatest effect within fixed budget.
One-way sensitivity analysis indicated, that T16 would
be optimal choice only when probability of complete cure
for T16 was 0,57 or probability of complete cure for
T12 was 0,41–0,43. In two-way sensitivity analysis T16
was optimal choice only when probablitity of complete
cure I3 and T12 or I4 and T12 were changed simulta-
neously. The treshold analysis suggests, that I3 and I4
would be optimal, when the price of itraconazole would
be decreased by 63%. CONCLUSION: In Poland T12
was the most cost-effective treatment of toenail onycho-
mycosis. 
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OBJECTIVE: To compare the economic impact of treat-
ing psoriatic patients in the Netherlands with calcipotriol
cream used daily combined with twice weekly UVB treat-
ment to emollient used daily combined with UVB given
three times weekly. METHODS: A pharmacoeconomic
analysis based on a Markov model was performed for the
Netherlands by combining information regarding 1) re-
duction in Psoriasis Assessment of Severity Index (PASI)
and relapse rates from a clinical study, 2) costs and stan-
dard clinical practice from a questionnaire survey and 3)
a Dutch dermatology consensus panel. Costs of UVB
treatments (staff, equipment, travelling), second line treat-
ment (PUVA), drug costs (calcipotriol, emollient) and in-
direct costs due to absence from work were included in
the analysis. RESULTS: The costs of treating psoriasis in
the Netherlands over 20 weeks with calcipotriol and twice
weekly UVB sessions is estimated to EUR 1,175.90. With
three weekly UVB sessions plus an emollient the costs is
estimated to EUR 1,212.14. CONCLUSION: Adding cal-
cipotriol to UVB phototherapy is a cost-neutral alterna-
tive to UVB phototherapy used with an emollient. But,
with calcipotriol and UVB as treatment strategy a num-
ber of essential beneficial effects for the patients are ob-
tained such as less exposure to potentially carcinogenic
radiation, less risk of developing photoaging of the skin and
less inconvenience to patients due to fewer UVB sessions.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of brinzolamide, a new topical carbonic
anhydrase inhibitor (CAI), with topical dorzolamide in
France, Italy and Portugal for the treatment of ocular hyper-
tension (OH) and primary open-angle glaucoma (POAG).
METHODS: High intra-ocular pressure (IOP) is the ma-
jor prognostic factor of POAG, and these two drugs were
developed to control it. Successful treatment was defined
as an IOP decrease of at least 5 mm Hg or any reduction
to a value below 21 mm Hg. Four double-masked well-
controlled randomized trials, three lasting 3-month and
one 12-months, compared the response rate of brinzola-
mide bid and tid versus dorzolamide tid, and the re-
sponse rate of brinzolamide bid versus bid dorzolamide
timolol combination bid. The local tolerance upon instil-
lation of the 2 drugs was compared through 2 dedicated
studies. The consequence of the instillation tolerance was
valued through an American HMO data base. The daily
cost of each drug took into account the number of drops
in a bottle, valued through a well-balanced analysis of
variance. In case of failure, either due to intolerance or
inadequate efficacy, the patients were treated with latan-
oprost. A model was developed to evaluate the cost of
initiating a treatment with a CAI (dorzolamide versus
brinzolamide) over 3 months. The economic perspective
taken was that of society. RESULTS: As a mono-therapy,
brinzolamide bid was found to be as efficacious as dor-
zolamide tid. Brinzolamide bid plus timolol was also as
efficacious as a combination of dorzolamide and timolol
bid. Stinging upon instillation with brinzolamide was far
less (P  0.0001) than with dorzolamide. The probability
that brinzolamide-treated patients would change therapy
was 1.28 (HMO study, P  0.05) less than the one of
dorzolamide-treated patients. The size of the brinzola-
mide drop is 18.7% smaller allowing 7 more therapy days
per bottle than dorzolamide mono-therapy when brin-
zolamide is used bid and 5 days when used tid. Conse-
quently, the breakeven price of brinzolamide was 10%
higher than dorzolamide in France and Portugal and 15%
in Italy, where CAIs were more often prescribed as mono-
therapy. CONCLUSION: Because (1) the daily cost of
brinzolamide is lower (2) brinzolamide can be prescribed
bid in mono-therapy (3) and brinzolamide stings less, our
model suggested that brinzolamide is a cost-effective al-
ternative in the treatment of OH and POAG.
